These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29536971)

  • 1. Clinical, immunological profile and follow up of patients with pemphigus: A study from India.
    Ramassamy S; Agrawal P; Sathishkumar D; Mathew L; Peter JV; Mani T; George R
    Indian J Dermatol Venereol Leprol; 2018; 84(4):408-413. PubMed ID: 29536971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus.
    Kushner CJ; Wang S; Tovanabutra N; Tsai DE; Werth VP; Payne AS
    JAMA Dermatol; 2019 Dec; 155(12):1404-1409. PubMed ID: 31642878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up.
    De D; Bishnoi A; Handa S; Mahapatra T; Mahajan R
    Indian J Dermatol Venereol Leprol; 2020; 86(1):39-44. PubMed ID: 31089006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of clinical and immunological factors associated with clinical relapse of pemphigus vulgaris in remission.
    Guliani A; De D; Handa S; Mahajan R; Sachdeva N; Radotra BD; Kishore K
    Indian J Dermatol Venereol Leprol; 2020; 86(3):233-239. PubMed ID: 31898637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.
    Reguiai Z; Tabary T; Maizières M; Bernard P
    J Am Acad Dermatol; 2012 Oct; 67(4):623-9. PubMed ID: 22261417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.
    Grando SA
    Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: defining a niche for these low toxicity agents.
    McCarty M; Fivenson D
    J Am Acad Dermatol; 2014 Sep; 71(3):475-9. PubMed ID: 24906610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
    Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
    Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose rituximab as an adjuvant therapy in pemphigus.
    Gupta J; Raval RC; Shah AN; Solanki RB; Patel DD; Shah KB; Badheka AD; Shah KB; Aggarwal NK; Ravishankar V
    Indian J Dermatol Venereol Leprol; 2017; 83(3):317-325. PubMed ID: 28366912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study.
    Sharma VK; Bhari N; Gupta S; Sahni K; Khanna N; Ramam M; Sethuraman G
    Indian J Dermatol Venereol Leprol; 2016; 82(4):389-94. PubMed ID: 27279296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylprednisolone pulse therapy plus adjuvant therapy for pemphigus vulgaris: an analysis of 10 years' experience on 312 patients.
    Gheisari M; Faraji Z; Dadras MS; Nasiri S; Robati RM; Moravvej H; Tehranchinia Z; Ghalamkarpour F; Namazi N; Nobari NN
    Dermatol Ther; 2019 Sep; 32(5):e13057. PubMed ID: 31400243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Pemphigus Vulgaris and Foliaceus with Adjuvant Rituximab Compared to Immunosuppression Alone: Real-Life Experience.
    Snast I; Spitzer L; Hodak E; Levi A; Mimouni D; Leshem YA
    Dermatology; 2021; 237(2):179-184. PubMed ID: 32756069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus.
    Londhe PJ; Kalyanpad Y; Khopkar US
    Indian J Dermatol Venereol Leprol; 2014; 80(4):300-5. PubMed ID: 25035353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oropharyngeal pemphigus vulgaris and clinical remission: a long-term, longitudinal study.
    Mignogna MD; Fortuna G; Leuci S; Ruoppo E
    Am J Clin Dermatol; 2010; 11(2):137-45. PubMed ID: 20141235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinic-epidemiological study of 148 patients of pemphigus at Lady Reading Hospital, Peshawar: a case series.
    Paracha MM; Sagheer F; Khan AQ
    J Pak Med Assoc; 2023 Mar; 73(3):659-662. PubMed ID: 36932776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus.
    Abasq C; Mouquet H; Gilbert D; Tron F; Grassi V; Musette P; Joly P
    Arch Dermatol; 2009 May; 145(5):529-35. PubMed ID: 19451496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current regimen of pulse therapy for pemphigus: minor modifications, improved results.
    Pasricha JS;
    Indian J Dermatol Venereol Leprol; 2008; 74(3):217-21. PubMed ID: 18583786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of pemphigus in the western region of Turkey: retrospective analysis of 87 patients.
    Bozdag K; Bilgin İ
    Cutan Ocul Toxicol; 2012 Dec; 31(4):280-5. PubMed ID: 22309241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulse versus oral methylprednisolone therapy in pemphigus vulgaris.
    Shahidi-Dadras M; Karami A; Toosy P; Shafiyan A
    Arch Iran Med; 2007 Jan; 10(1):1-6. PubMed ID: 17198445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enteric-coated mycophenolate sodium as a steroid-sparing agent in pemphigus treatment: a retrospective study.
    De Simone C; Caldarola G; Perino F; Venier A; Guerriero G
    Dermatol Ther; 2012; 25(2):219-22. PubMed ID: 22741942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.